8 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 14 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 8, Active not recruiting 3, Terminated 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow lofexidine: new trials by email Literature Review of lofexidine trials Research Report on lofexidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal LFX/PGB, LFX/PLA-PGB - Opiate Withdrawal Syndrome, Opioid Use | Phase 2 | Terminated | University of Pennsylvania | 112 | 2024-09-01 | 2026-11-16 |
| Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids Standard of Care with Lofexidine, Standard of Care without Lofexidine - Opioid Withdrawal (Disorder) | Phase 2 | Active not recruiting | BioCorRx Pharmaceuticals Inc | 24 | 2023-10-02 | 2025-10-01 |
| Sublingual Dexmedetomidine for Treating Opioid Withdrawal BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Active not recruiting | New York State Psychiatric Institute | 160 | 2023-02-28 | 2026-10-28 |
| Evaluating Buspirone to Treat Opioid Withdrawal Buspirone, Lofexidine, Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 2 | Recruiting | University of Maryland, Baltimore | 100 | 2022-12-15 | 2026-08-24 |
| Assessing a Clinically-meaningful Opioid Withdrawal Phenotype Hydromorphone, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment - Opioid Withdrawal, Opioid Use Disorder | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 60 | 2021-12-01 | 2026-11-12 |
| Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans Lofexidine, Placebo oral tablet - Post Traumatic Stress Disorder, Opioid-use Disorder | Phase 2 | Completed | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 84 | 2021-03-09 | 2026-05-08 |
| Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal Pregabalin 200 MG capsules, Placebo oral tablet, Lofexidine 0.18Mg Tab - Opioid Withdrawal | Phase 2 | Completed | University of Pennsylvania | 90 | 2020-12-17 | 2024-09-19 |
| An Innovative Intervention for OUD Treatment Bridge Device, Lofexidine, Placebo - Opioid-Related Disorders, Opioid Dependence | Phase 2 / Phase 3 | Completed | Johns Hopkins University | 36 | 2020-11-15 | 2026-06-09 |
| Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment Lofexidine 0.18 MG - Opioid-use Disorder | Phase 2 | Completed | New York State Psychiatric Institute | 20 | 2019-09-01 | 2021-12-09 |
| Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal Lofexidine, Placebo - Opioid Withdrawal (Disorder) | Phase 2 | Terminated | USWM, LLC (dba US WorldMeds) | 4 | 2019-08-02 | 2024-10-21 |
| Impact of Lofexidine on Stress, Craving and Opioid Use Lofexidine, Placebo - Opioid-use Disorder, Opiate Dependence | Phase 2 | Completed | Medical University of South Carolina | 112 | 2019-06-26 | 2025-02-07 |
| Combined Pharmacotherapy for Cannabis Dependency Dronabinol, Placebo, Lofexidine - Cannabis Dependence, Marijuana Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 156 | 2010-01-01 | 2019-04-24 |
| Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse Lofexidine, dronabinol, Marijuana - Marijuana Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 8 | 2005-08-01 | 2013-02-05 |
| Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1 Lofexidine, Placebo - Opioid-Related Disorders | Phase 2 | Completed | Yale University | 86 | 2005-02-01 | 2015-07-30 |
Opioid-Related Disorders (8) · Marijuana Abuse (2) · Anxiety Disorders (1) · Stress Disorders, Post-Traumatic (1)
New York State Psychiatric Institute (4) · University of Maryland, Baltimore (2) · University of Pennsylvania (2) · BioCorRx Pharmaceuticals Inc (1) · Johns Hopkins University (1) · Medical University of South Carolina (1) · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (1) · USWM, LLC (dba US WorldMeds) (1) · Yale University (1)
United States (14)
Cecilia Bergeria, Ph.D. (1) · Christopher D. Verrico, PhD (1) · Eric Strain (1) · Frances R Levin, M.D. (1) · John Peppin, DO (1) · Kelly E Dunn, Ph.D, M.B.A. (1) · Margaret Haney, Ph.D. (1) · Rajita Sinha (1) · Sandra Comer, Ph.D (1) · Stuart Watson (1) · Thomas R Kosten, MD (1)
P50DA009236 (1), R01DA019239 (1), R01DA048761 (1), R01DA052937 (1), U54DA016511 (1), UG3DA056247-01 (1)